CXCL1 and systemic lupus erythematosus: Compared to the autophagy-inactive SLE-EV treatment group, the Rapa-SLE-EV treatment group showed significantly reduced plasma levels of BAFF, IL-4, IL-5, GM-CSF, and CXCL1; these effects were not observed in the FBS-treated groups.